Purdue Pharma and Exicure Inc. have entered into a strategic research partnership, option and license agreement in order to determine and develop treatments for psoriasis and other diseases amenable to a gene regulation approach.
For this project, the two companies plan to utilize Exicure’s Spherical Nucleic Acid (SNA).
“This long-term strategic collaboration agreement represents a significant expansion of Purdue’s pipeline and provides us with the potential to further our mission of developing novel therapies for patients with chronic conditions,” Purdue Pharma President and CEO Mark Timney said. “We look forward to combining Exicure’s SNA technology and deep expertise in this field with Purdue’s resources and expertise in clinical studies, regulatory affairs and commercialization for the benefit of patients.”
Purdue will keep full global development and commercial rights to AST-005 when exercising its option.
“Given the broad potential of SNA technology, we want to forge long-term strategic relationships with best-in-class companies,” Exicure CEO Dr. David Giljohann said. “As we were looking for a global leader with a proven track record in the development and global commercialization of treatments for patients with chronic conditions, we were very impressed with the Purdue Pharma’s clinical and commercial capabilities.”
